GCGR具有升糖作用，为何还能成为减重靶点？
肥胖及相关代谢性疾病不仅表现为能量摄入和脂肪储存增加，还伴随肝脏糖脂代谢、底物利用和氨基酸稳态异常。GCGR是调控空腹状态下肝脏底物动员的重要Class B1 ...
主题
FGF21
以下是知识库中与该主题相关的实验方案、常见问题、指南与技术文章。
4 项资源 · 实验方案、常见问题与文章
Why Can GCGR Become a Weight-Loss Target Despite Its Glucose-Raising Effect?
Obesity and related metabolic diseases are characterized not only by increased energy intake and fat storage but also by abnormalities in hepatic glucose and lipid metabolism, substrate utilization, and amino acid homeostasis. GCGR is an important Class B1 GPCR that regulates hepatic substrate ...
Pathogenesis, Therapeutic Targets, and Drug Development for Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH)
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
代谢功能障碍相关脂肪性肝炎（MASH/NASH）的 发病机制、治疗靶点与药物开发
代谢功能障碍相关脂肪性肝炎由肝脂肪沉积、脂毒性、胰岛素抵抗、炎症和纤维化共同驱动。靶向脂质代谢、核受体、肠促胰素及FGF信号已成为药物开发的主要方向。
相关主题
同一批资源中共同出现的其他主题。
危险品化学品经营许可证（带存储）